Core Viewpoint - Dajia Weikang (301126) responded to investor inquiries on November 6, indicating that the number of shareholders as of October 31, 2025, can be found in previously disclosed information [1] Summary by Categories - Company Information - Dajia Weikang has provided information regarding its shareholder count as of a future date, October 31, 2025 [1]

Core Viewpoint - The company, Dajiahui Kang, has provided information regarding the distribution of its subsidiaries' pharmacies in Hainan province, specifically in cities such as Haikou, Wenchang, Qionghai, and Ding'an [1] Company Summary - Dajiahui Kang operates two main subsidiaries: Hainan Dajiahui Kang Pharmacy Chain Co., Ltd. and Hainan Dajiahui Kang Hongchuntang Pharmacy Chain Co., Ltd. [1] - The pharmacies are primarily located in Haikou, Wenchang, Qionghai, and Ding'an, indicating a focused regional presence in Hainan [1]

Core Points - The company announced that from September 1, 2025, to November 5, 2025, a shareholder holding more than 5%, Director Zhong Xuesong, will reduce his holdings by a total of 1,000,800 shares, accounting for 0.49% of the company's total share capital [1] - Following this reduction, Zhong's shareholding will decrease from 19,288,400 shares to 18,287,600 shares, with his ownership percentage dropping from 9.39% to 8.90% [1] - This reduction in holdings is part of a previously announced plan to reduce up to 3,500,000 shares, which represents 1.70% of the total share capital, and the plan has not yet been fully executed [1]

Group 1 - The company, Dajia Weikang (301126), reported that as of October 31, 2025, the number of shareholders is 15,923 [1]

Core Viewpoint - Hunan Dajia Weikang Pharmaceutical Co., Ltd. is preparing for an IPO in Hong Kong, aiming to raise funds for expanding its retail network, upgrading logistics, enhancing marketing, and supplementing working capital [1] Group 1: Company Overview - Dajia Weikang is a comprehensive pharmaceutical service provider focused on offering a full range of health services, including the distribution and retail of pharmaceuticals and medical devices [1] - The company operates a distribution network and chain pharmacies across Hunan Province and other regions, providing products and professional services such as medication consultation and health management [1] - Dajia Weikang has established long-term partnerships with well-known domestic and international pharmaceutical manufacturers, ensuring timely and safe drug supply through integrated supply chain resources and digital management systems [1] Group 2: IPO Details - The IPO is sponsored by CITIC Construction Investment International and Huatai Financial Holdings (Hong Kong) [1] - The funds raised from the IPO will be allocated to the following purposes: expanding and optimizing the pharmaceutical retail network, upgrading logistics centers and supply chain management systems, enhancing marketing and brand building, and supplementing working capital for general corporate purposes [1]

Core Viewpoint - Dajia Weikang (301126) announced the resignation of its Vice President, Li Yulan, due to personal reasons, effective immediately, and she will no longer hold any position within the company [1] Group 1 - The company’s board of directors received the resignation report from Li Yulan [1] - Li Yulan's resignation is attributed to personal reasons [1] - Following her resignation, Li Yulan will not serve in any capacity within the company [1]

Company Overview - Dajia Weikang (SZ 301126) announced the resignation of Deputy General Manager Li Yulan due to personal reasons, effective immediately, with her term originally set from October 17, 2023, to October 9, 2026 [1] - Following her resignation, Li Yulan will no longer hold any position within the company [1] Financial Performance - For the first half of 2025, Dajia Weikang's revenue composition is as follows: retail accounted for 51.84%, wholesale for 44.29%, industrial revenue for 2.98%, other income for 0.7%, and hospital revenue for 0.19% [1] - As of the report date, Dajia Weikang's market capitalization stands at 2.5 billion yuan [1]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-070 湖南达嘉维康医药产业股份有限公司 关于高级管理人员离职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 10 月 31 日 2 1 展做出的贡献表示衷心感谢！ 特此公告。 湖南达嘉维康医药产业股份有限公司董事会 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）董事会于近日收 到公司副总经理李玉兰女士的离职报告，李玉兰女士因个人原因申请辞去公司副 总经理职务，其原定任期为 2023 年 10 月 17 日至 2026 年 10 月 9 日，根据《中华 人民共和国公司法》（以下简称《公司法》）《公司章程》《董事、高级管理人 员离职管理制度》的规定，李玉兰女士的离职报告自送达董事会之日起生效。辞 职后，李玉兰女士不再担任公司任何职务。 截至本公告披露日，李玉兰女士直接持有公司股份 165,000 股，通过长沙同展 咨询企业合伙企业（有限合伙）间接持有公司股份 100,000 股，合计占公司总股本 比例为 0.13%，其配偶及其他关联人未持有公司股份。李玉兰女士离职后将严格 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-069 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 13 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2025 年 11 月 13 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 湖南达嘉维康医药产业股份有限公司 关于召开 2025 年第三次临时股东会的通知公告 本公司董事会及全体董事保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：本次股东会的召集、召开符合《中华人民共 和国公司法》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 13 日 14:30 6、会议的股权登记日：2025 年 11 月 10 日 7、 ...

2025年10月28日，达嘉维康(301126.SZ)发布2025年第三季报。截至2025年10月27日，共有4个机构投资 者披露持有达嘉维康A股股份，合计持股量达2196.03万股，占达嘉维康总股本的10.69%。其中，机构 投资者包括长沙同嘉投资管理合伙企业(有限合伙)、桐乡稼沃云枫股权投资合伙企业(有限合伙)、宁波 梅山保税港区量吉股权投资合伙企业(有限合伙)、宁波梅山保税港区淳康股权投资合伙企业(有限合 伙)，机构投资者合计持股比例达10.69%。相较于上一季度，机构持股比例合计下跌了2.33个百分点。 外资态度来看，本期较上一季未再披露的外资机构即BARCLAYS BANK PLC。 公募基金方面，本期较上一季未再披露的公募基金共计34个，主要包括诺安多策略混合A、国金量化多 因子A、国金量化精选A、西部利得量化优选一年持有期混合A、富荣福耀混合A等。 ...